Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Lymphoma, Large B-Cell, Diffuse 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Triple Negative Breast Neoplasms 2 Rectal Neoplasms 2 Gallbladder Neoplasms 2 Colonic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Thymoma 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Salivary Gland Neoplasms 1 Recurrent Squamous Cell Carcinoma of the Nasopharynx 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1

Interventions

Temozolomide 69 Bevacizumab 40 Radiotherapy 22 Magnetic Resonance Spectroscopy 20 Irinotecan 17 Specimen Handling 10 Carboplatin 10 Carmustine 9 X-Rays 7 Radiation 7 olaparib 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Nivolumab 6 Everolimus 6 Cyclophosphamide 6 Biopsy 6 trametinib 5 Thalidomide 5 Cisplatin 5 pembrolizumab 4 palbociclib 4 fluorodopa F 18 4 erdafitinib 4 dabrafenib 4 Lomustine 4 Etoposide 4 Drug Therapy 4 Doxorubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × MK 2206 × Clear all

NCT01249105 2016-03-10

MK-2206 for Recurrent Malignant Glioma

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡